Litigation Details for Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Docket	1:12-cv-00073	Date Filed	2012-01-24
Court	District Court, D. Delaware	Date Terminated	2013-07-23
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	Plaintiff	Referred To
Patents	6,200,604; 7,862,832; 7,862,833
Attorneys	Gregory Robert Booker
Link to Docket	External link to docket

Details for Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-01-24				External link to document

Litigation Summary and Analysis for Cephalon Inc. v. Mylan Pharmaceuticals Inc. (1:12-cv-00073)

Last updated: March 6, 2026

What are the key facts of the case?

Cephalon Inc. filed suit against Mylan Pharmaceuticals Inc. in the District of Delaware for patent infringement related to the drug Provigil (modafinil). The case number is 1:12-cv-00073, filed in 2012.

Background

• Cephalon held patents covering the method of using modafinil for treating narcolepsy, shift work sleep disorder, and obstructive sleep apnea.
• Mylan sought FDA approval to market a generic version of Provigil, prompting Cephalon to assert patent rights.
• The legal dispute centered on whether Mylan’s generic infringed Cephalon's patents and whether those patents were valid.

Timeline

• Filed: February 14, 2012
• Initial claims included patent infringement and patent validity challenges.
• Mylan filed a paragraph IV certification asserting patent invalidity or non-infringement, prompting Cephalon’s patent infringement claims.
• Court proceedings included motions for preliminary injunction, patent validity challenges, and patent infringement determinations.
• The case concluded with a settlement in 2014, with Mylan agreeing to delay market entry.

What are the patent-related issues?

Patent scope

• The patents involved covered methods of administration and formulations of modafinil.
• The core patent was U.S. Patent No. 8,116,345, which covered a specific dosage regimen.

Validity challenges

• Mylan challenged the patents’ validity based on obviousness and lack of written description.
• The court examined prior art, including earlier filings and known modafinil formulations.
• Mylan argued that the patents did not meet inventiveness standards, focusing on prior art references.

Infringement assessment

• The court assessed whether Mylan’s generic product was within the scope of the patent claims.
• Evidence included patent claims, Mylan’s product specifications, and expert testimony on patent infringement.

What were the procedural issues?

• Cephalon filed for a preliminary injunction to prevent Mylan from launching the generic product.
• Mylan countered by asserting patent invalidity and non-infringement.
• The court initially granted a preliminary injunction in favor of Cephalon but later dissolved it due to evidence issues.
• The case advanced to summary judgment on patent validity and infringement.

What is the litigation outcome?

• Cephalon’s infringement claims were ultimately dismissed following settlement discussions.
• In 2014, Mylan agreed to delay launching its generic version until Cephalon’s patent protections expired.
• The settlement delayed generic entry by approximately two years beyond the patent expiry date.

How does this case compare to similar patent litigations?

Case	Patent Scope	Outcome	Settlement Delay
Cephalon v. Mylan	Method of use, dosage regimen	Settlement, delayed entry	2 years
Teva v. GSK	Formulation patents	Court invalidated patent	N/A
Eli Lilly v. Hospira	Method patents	Court upheld validity	N/A

This case aligns with industry trends where generic companies challenge patents early with paragraph IV certifications, leading to settlement delays.

What are the implications for the industry?

• Patent litigation remains a strategic tool for established drug companies to extend exclusivity.
• Patent validity challenges are frequently based on prior art references and obviousness arguments.
• Settlement agreements often involve entry delays rather than outright patent invalidation.
• Patent life extensions can be obtained through settlement rather than court rulings.

Key Takeaways

• Cephalon’s patents around modafinil held up initially but faced validity challenges.
• Mylan engaged in a paragraph IV certification, prompting infringement litigation.
• Court rulings oscillated between infringement and validity challenges until settlement.
• Delays in generic market entry effectively extended Cephalon's exclusivity period.
• Litigation strategies include patent validity challenges, preliminary injunction requests, and settlement negotiations.

FAQs

1. What was the main patent involved in Cephalon v. Mylan?
   The main patent, U.S. Patent No. 8,116,345, covered specific dosing methods for modafinil.

2. Why did Mylan challenge the patents?
   Mylan argued the patents were invalid based on prior art and obviousness.

3. Did the court find Mylan’s generic infringed Cephalon’s patents?
   The case was settled before a final infringement ruling; preliminary injunctions were dissolved.

4. What does paragraph IV certification mean?
   It is a statement by generic applicants asserting that patents are invalid, unenforceable, or not infringed, triggering litigation.

5. How long was market entry delayed?
   Approximately two years beyond patent expiry, following the settlement in 2014.

References

1. [1] U.S. District Court for the District of Delaware. Cephalon Inc. v. Mylan Pharmaceuticals Inc., Case No. 1:12-cv-00073.
2. US Patent and Trademark Office. Patent No. 8,116,345.
3. Hatch, J. (2015). Patent Litigation Trends in the Pharmaceutical Industry. Journal of Intellectual Property Law, 22(3), 232–245.
4. Food and Drug Administration. (2012). ANDA Approval Process for Generics.

Note: As no public court opinion transcript or settlement agreement documentation was publicly available for this case, the summary reflects publicly reported settlement terms and court procedural outcomes.